Recipient Reporting Data Model: Fill & Download for Free

Mr. Avinash P. GandhiMr. Avinash P. Gandhi received his Bachelor's Degree in Mechanical Engineering from Birla Institute of Technology, Mesra and he has completed Senior Management programmes at Indian Institute of Management and Administration Staff College of India.Mr. Gandhi served as a Special Advisor to Asia Automotive Acquisition Corp. since June 20, 2005. From 1998 to 2002, Shri. Gandhi had been the President of Hyundai Motors India and from September 1994 to June 1997, he served as the Chief Executive Officer of Bhartia Cutler Hammer (now a part of Eaton Corporation). From June 1997 to June 1998, Mr. Gandhi was Group Chief Executive of a Conglomerate of seven companies having tie-ups with leading global electrical products manufacturers.Mr. Avinash P. Gandhi has rich years of experience in engineering and various managerial positions. He held top leadership positions in prestigious organizations for nearly two decades in a professional career spanning forty years. From 1969 to 1994, he served in a number of positions with Tata Motors and Escorts Limited including that of Director on Board of Escorts Claas, a start up joint venture project with the largest Indian self propelled combine harvester company.Mr. Gandhi’s other positions of eminence include:The Chairman of the Board of Directors of Fag Bearings India Ltd.Independent & Non-Executive Director of Havells India Ltd.Director of Uniproducts (India) Ltd.Member of Advisory Board of NuVeda Learning Pvt. Ltd.His other Directorship’s include Independent Lumax Industries Ltd., Fairfield Atlas Ltd., Panalfa Automotive Pvt. Ltd., Continental Engines Ltd., Mahavir Aluminium Limited, Minda HUF Ltd., Indo Alusys Ltd., Avinar Consulting Pvt. Ltd., Avinar Service Pvt. Ltd. and Pan Alfa Auto Ektrie Pvt. Ltd.Mr. S. N. AgarwalMr. S.N. Agarwal, a graduate engineer from Birla Institute of Technology, Mesra and an alumnus of Harvard Business School (AMP- 1985) is the Chairman of the BHORUKA Group.He has been a Senior Executive Committee Member of Federation of Indian Chambers of Commerce & Industry, (FICCI) since 1985. He has been the Chairman of various National Committees of FICCI on Power, Non-conventional energy, Logistics etc. He is the President of Karnataka State Council of FICCI-New Delhi and he is also the Vice President of SAARC Chamber of Commerce & Industry representing India.Mr. S N Agarwal’s other positions include Member, Governing Board - Indian Institute of Management (Bangalore), Chairman of the Committee on Finance and Campus Development of Indian Institute of Management Bangalore (IIM-B), Member - World Presidents Organization. He was also the Past President of All India Organization of Employers, (AIOE).Dr. Ganesh NatarajanDr. Ganesh Natarajan is Deputy Chairman and Managing Director of Zensar Technologies Limited, a Global firm that transforms Technology and Processes for Fortune 500 companies. Dr. Natarajan has been one of the most successful professionals in the Indian Information Technology Industry, having earlier been part of two major success stories in IT Training and Consulting, NIIT and APTECH. During his ten-year stint as CEO of Aptech he grew the company’s revenues fifty times and listed it on the Indian and London Stock Exchanges.A Gold Medallist in Mechanical Engineering from Birla Institute of Technology, Mesra he has completed his PhD in Knowledge Management at IIT Bombay. He is the author of three McGraw Hill Books on Business Process Reengineering and Knowledge Management and has also authored a book titled “Winds of Change”. He is a regular columnist for India’s premier Business and IT magazines.Dr. Ganesh Natarajan was named “CEO of the Year” by the Asia Pacific HR Conference in 1999 and received the Wisitex Foundation’s CEO of the Decade – Knowledge Award from India’s Minister for Information Technology in 2000. In July 2005, he received the Asia HRD Congress Award for Contributions to the Organisation through HR. He was one of nineteen finalists at the Ernst & Young Entrepreneurs of the Year Award 2005 where he was recognized for his exemplary leadership skills and business acumen.Dr. Natarajan chairs the Outsourcing Forum of the Confederation of Indian Industries in Western India and is also a member of the Executive Council of NASSCOM, India’s premier IT and BPO Association. He has been elected Chairman of the NASSCOM Innovation Forum for 2005-07.Mr. Deven SharmaMr. Deven Sharma holds a bachelor's degree from the Birla Institute of Technology, Mesra, having graduated in Mechanical Engineering in the year 1977. He holds a Master's degree from the University of Wisconsin and a doctoral degree in Business Management from Ohio State University.Deven Sharma was named president of Standard & Poor's in August 2007. Standard & Poor's, a division of The McGraw-Hill Companies, is the world's foremost provider of financial market intelligence, including independent credit ratings, indices, risk evaluation, investment research and data. With approximately 8,500 employees, including wholly owned affiliates located in 21 countries, Standard & Poor's is an essential part of the world's financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions.Prior to being named president, Mr. Deven Sharma served as Executive Vice President, Standard & Poor’s, where he was responsible for Investment Services and Global Sales. The businesses include Investment Data & Information, Research and Portfolio services. Prior to this, he spent five years as Executive Vice President, Global Strategy for The McGraw-Hill Companies, where he led the expansion into digital markets, geographies and new growth areas, as well as acquisitions. He also oversaw McGraw-Hill Ventures.Mr. Sharma joined The McGraw-Hill Companies in January 2002 from Booz Allen Hamilton, a global management consulting company, where he was a partner. During his 14 years with that firm, he provided guidance to client companies on business strategy and globalization, as well as on branding and sales management. Much of his experience includes work with global corporations in U.S., Latin America, Europe and parts of Asia. Prior to Booz Allen, he worked with manufacturing companies, Dresser Industries and Anderson Strathclyde.Mr. Sharma has authored several publications on competitive strategy, customer solutions, sales and marketing. He is a Board member of CRISIL, The US-China Business Council and Asia Society Business Council.Mr. Gurdeep Singh PallMr. Gurdeep Singh Pall is the corporate vice president for the Office Communications Group at Microsoft Corp. and part of the Microsoft Business Division's senior leadership team. He is responsible for vision, product strategy and business development, and R&D for Microsoft's Unified Communications offerings, including Microsoft Office Communications Server, Microsoft Office Communicator, Microsoft Office Live Meeting service and Microsoft Office Communications Online.Mr. Pall joined Microsoft in January 1990 as a software design engineer. He has worked on many breakthrough products in his tenure, starting with LAN Manager Remote Access Service. He was part of the Windows NT development team, working on the first version of Windows NT 3.1 in 1993 as a software design engineer, all the way through Windows XP in 2001 as general manager of Windows Networking. During his work on Windows, he led design and implementation of core networking technologies such as PPP, TCP/IP, UPnP, VPNs, routing and Wi-Fi, and parts of the operating system. He co-authored the first VPN protocol in the industry – Point-to-Point Tunnelling Protocol (PPTP) – which received the prestigious Innovation of the Year award from PC Magazine in 1996. He also authored several documents and standards in the networking area in the Internet Engineering Task Force (IETF) standards body in the mid-1990s. Mr. Pall was appointed general manager of Windows Real-Time Communications efforts in January 2002 and helped develop a broad RTC strategy that led to the formation of the Real Time Collaboration division and acquisition of PlaceWare Inc. (now called Microsoft Office Live Meeting). Since then, Pall has led acquisitions of Page on media-streams.com AG and Parlano and key industry partnerships. Microsoft's Unified Communications efforts have received many technical and design industry awards. He was named one of the 15 Innovators & Influencers Who Will Make A Difference in 2008 by Information Week. Mr. Gurdeep Singh Pall recently co-authored "Institutional Memory Goes Digital," which was published by Harvard Business Review as part of "Breakthrough Ideas for 2009" and was presented at the World Economic Forum 2009 in Davos, Switzerland.Mr. Pall has more than 20 patents (in process or approved) in networking, VoIP and collaboration areas. He holds a master's degree in computer science from the University of Oregon and a graduate degree in computer engineering from Birla Institute of Technology, Mesra, Ranchi in India.Mr. Sanjay NayakMr. Sanjay Nayak is the Co-founder & Chief Executive Officer of Tejas Networks, a leading optical networking product company from India. Mr. Nayak is a technologist with over 18 years of industry experience in India as well as the USA. Prior to founding Tejas, he held senior management position in globally leading Electronic Design Automation companies such as Synopsys (where he was the Managing Director of Synopsys-India) and earlier at Cadence Design Systems. Mr. Nayak holds an M.S. in Electrical and Computer Engineering from North Carolina State University, Raleigh and B.E in Electronics and Communication Engineering from Birla Institute of Technology, Mesra.Mr. Sukant SrivastavaSukant Srivastava is Managing Director and Country Manager for Convergys Corporation’s Customer Care business in India. He is responsible for overseeing the operations of Convergys’ eight contact centres and 11,000+ Customer Care employees in India, directing relationships with National Government officials and representing Convergys in key industry forums and associations. Additionally, he focuses on driving Convergys’ Relationship Management brand position in India, enabling talent acquisition and continued leadership in the rapidly growing business process outsourcing market. Mr. Srivastava reports to Clint Streit, president of Customer Care, and is located in Gurgaon, India. Prior to joining Convergys, Mr. Srivastava served in a variety of global leadership roles with Keane, Inc. His most recent assignment was as managing director for Keane’s Indian operations. In this position he served as a transformation agent for enterprise-wide change initiatives, including a shift to a globally integrated business model. Previously, he was vice president of Global Services Integration for Keane.Mr. Srivastava holds a Bachelor’s degree in Electrical Engineering from the Birla Institute of Technology in Ranchi, India and a Master’s degree in Business Administration from the University of North Florida.Dr. Shree K. NayarDr. Shree K. Nayar did BE in electrical Engineering from Birla Institute of Technology, Ranchi, India in the year 1984. He received his PhD degree in Electrical and Computer Engineering from the Robotics Institute at Carnegie Mellon University in 1990. He is currently the T. C. Chang Professor of Computer Science at Columbia University. He co-directs the Columbia Vision and Graphics Center. He heads the Columbia Computer Vision Laboratory (CAVE), which is dedicated to the development of advanced computer vision systems. His research is focused on three areas; the creation of novel cameras, the design of physics based models for vision, and the development of algorithms for scene understanding. His work is motivated by applications in the fields of digital imaging, computer graphics, and robotics.Dr. Shree K. Nayar has received best paper awards at ICCV 1990, ICPR 1994, CVPR 1994, ICCV 1995, CVPR 2000 and CVPR 2004. He is the recipient of the David Marr Prize (1990 and 1995), the David and Lucile Packard Fellowship (1992), the National Young Investigator Award (1993), the NTT Distinguished Scientific Achievement Award (1994), the Keck Foundation Award for Excellence in Teaching (1995) and the Columbia Great Teacher Award (2006). In February 2008, he was elected to the National Academy of Engineering.Dr. Arup Roy ChoudhuryDr. Arup Roy Choudhury is a firm believer in achieving team-excellence through transformational shift to proactive, positive and personalized approach. Having experience in private and public sector organizations, Dr. Arup Roy Choudhury has an illustrious career of about 35 years during which he has been holding the position of CEO for over thirteen years. An engineering graduate from BIT-Mesra, he completed his post graduation and doctorate from IIT-Delhi and fol lows the motto “Sankalpa Shuddha Hi Siddha” i.e. if your intentions are pure, you are bound to succeed.Becoming the youngest CEO of a CPSE at the age of 44 years, he scripted a stunning turnaround story as CMD when he transformed NBCC, which was a sick company with negative net-worth and salary backlog in 2001, into a blue-chip enterprise having 'Schedule A’ and ‘Mini Ratna’ status bestowed upon it by the Government of India. The transformational turnaround of the Company brought about by him enabled NBCC’s turnover grow about 10 times and net-worth over 500 times during his tenure of nine-and-a-half years at the helm (Annexure-I). He pulled NBCC out of the abyss and catapulted it into the distinguished league of ‘Top Ten CPSEs’. Under him, NBCC broadened its business horizons and paid its maiden dividend to the Govt. of India for the year 2006-07, after 45 years of its incorporation.Dr. Choudhury now heads NTPC Limited, the 10th largest power producer in the world and ranked as #1 Indepedent Power Producer by Platts (part of the prestigious McGraw Hill Group). NTPC is acknowledged as the best company in the world for capacity utilization. NTPC is also one of the seven largest Central Public Sector Undertakings of India, designated as a ‘Maharatna’.Since taking over as CMD-NTPC in September, 2010, Dr. Choudhary has been positioning the enterprise on course to become the largest and best power producer in the world.In a period of three and a half years of Dr. Choudhury’s leadership, NTPC has already added about 10,800 MW, which is over one fourth of its total installed capacity of over 43,019 MW built in over 38 years. NTPC’s turnover is around Rupees 68,800 crore (about USD 12.5 Billion). NTPC's financial performance in 2012-13 has been exceptionally strong with a Profit After Tax (PAT) of about Rs. 12,600 crore (about USD 2.3 billion), an increase of about 37% over the previous year's PAT.Dr. Choudhury steered the process of ‘Offer for Sale’ for disinvestment of 9.5% stakes of the Government of India in NTPC, garnering over USD 2 billion (About Rs. 11,500 Cr). This was oversubscribed by 1.7 times with 45% coming from foreign investors. NTPC's issue for Tax Free Bond of Rs. 1,000 crore in December, 2013 received overwhelming response from the investors with oversubscription of 3.37 times.Dr. Choudhury, as Chairman of Standing Conference of Public Enterprises (SCOPE) - the apex forum of over 200 Central Public Sector Enterprises (CPSEs) in India - for two consecutive terms of two years each (From April 2009 to March 2013) effectively led policy advocacy for greater empowerment of these enterprises. He led a team of select CEOs to the Prime Minister and still remains the flag-bearer of Central PSUs.Dr. Choudhury figures at # 40 among 'India Inc's 100 Most Powerful CEOs 2013' in the list released by The Economic Times.Dr. Choudhury has received several national and international awards, including the Award for ‘The Best Organizational Turnaround’ from Hon. President of India in 2006, ‘Top Ten PSU and Turnaround Award’ from Hon. Prime Minister of India in 2007 and ‘Best Individual Leader of a Public Sector Enterprise’ from Hon. Prime Minister of India in 2010.Dr. Choudhury has captured his rich experiences and insights into a very well received book titled – 'Management by Idiots'.Mr. Anjan LahiriMr. Anjan Lahiri serves as President and CEO of MindTree’s IT Services business and is stationed in Bangalore. In this role he is responsible for all aspects of MindTree’s IT Services business around the world.Prior to relocating to Bangalore in 2008, Anjan spent five years in London setting up and then growing MindTree’s European Operations. In 1999 when he joined MindTree as a part of the founding team, he helped set up MindTree’s New Jersey office and then led MindTree’s US West Coast Operations from San Jose, California from 2000 to 2003 before relocating to London.Prior to MindTree, Anjan was a Director with Cambridge Technology Partners. He was part of the initial group, which started Cambridge’s internet services consulting practice. Anjan started his professional career with Wipro Infotech in 1987. By 1991 when he left to pursue higher studies in the US, he was a Territory Manager in Wipro’s Kolkata office.Anjan Lahiri received a BE in electronics engineering from the Birla Institute of Technology, Mesra, Ranchi.Mr. Pawan Bhageria1983 Mechanical Engineering-Gold Medalist and MBA from XLRI, Jamshedpur His 26 years of experience in Automotive / IT Industry includes Manufacturing, New Plant Commissioning Projects & all aspects of Information Technology with special focus on automotive & manufacturing industry. He has held leadership positions in large corporations of repute in India and abroad in Global cross-cultural business and technical environment.Key areas of work :Business aligned IT strategic planning and its execution,Process re-engineering & Efficiency Modeling .ERP (SAP/Oracle/Others) Global Implementation.IT Operations Managemen.IT Audits & ComplianceLarge Contract Negotiations & Vendor ManagementOrganization Change ManagementHe was Head of IT for Tata Motors & Strategic Account Manager at Tata Technologies before joining General Motors in 2006. Currently part of GM International Operations as IT Director.Mr. Himanshu KapaniaMr. Himanshu Kapania has been the Managing Director of Idea Cellular Limited since April 1, 2011. Mr. Kapania served as Deputy Managing Director at Idea Cellular Limited until April 1, 2011. He served as the Chief Operating Officer - Corporate and Director of Operations for Idea Cellular Limited.Mr. Kapania joined Idea in September 2006 with over 21 years of industry experience. He worked with Reliance Infocomm as their Chief Executive Officer for Northern Operations covering Punjab, Haryana and HP as for three years, with IDEA Cellular Ltd., as Chief Operating Officer for over six years, with Network Ltd., as Dy. General Manager - Marketing for three and a half years, with Shriram Honda as Manager Marketing for over three years and with DCM Toyota as Sr. Executive for five years. Mr. Kapania serves as a Director of Idea Cellular Limited. He is a BE in Electrical & Electronics from Birla Institute of Technology, Ranchi and a postgraduate from the Indian Institute of Management, BangaloreM. M. Singh (Batch of 1974)M M Singh is the Chief Operating Officer, Maruti Suzuki India LimitedHe leads Production vertical at Maruti Suzuki India Limited. He is responsible for rolling out 1.2 million cars from Maruti stable every year with assets under control (AUC) of USD 5 billion (Rs 30,000 crores). All manufacturing facilities at Gurgaon, Manesar , Gujarat reports to him. He leads a team of 20,000 people at 10 plants consisting of more than 150 departments.His leadership led to production of high Quality cars which were exported to EU, Latin America and Middle East, and Topping CSI and APEAL ratings in India. Every year Maruti exports about 120,000 cars made in India. During his leadership an Indian manufactured car became World’s largest selling auto brand, Alto, beating models like Polo and Accord.He is Chairman of SIAM ( Society of Automobile Engineers) Logistics, Co-chairman of FICCI Manufacturing National Committee and Chairman of CII North manufacturing committee.He has received inspired manufacturing fraternity with his patented thought process called “Production Managament System” which has set revolution in manufacturing sphere by combining Japanese practices with Indian wisdom and capturing the passion of western management.M M Singh is from the BIT BE (ECE) Batch of 1974Sudhir Mohan TrehanSudhir Mohan Trehan is Executive Chairman of Avantha Power & Infrastructure Limited and Vice Chairman of Crompton Greaves Limited.A gold medallist in mechanical engineering, he graduated from Birla Institute of Technology, Ranchi. He received his Master’s degree in operational research from State University of New York at Stony-Brook, U.S.A., and successfully completed the Advanced Management Program (AMP) from Harvard Business School, Boston, U.S.A.He joined Crompton Greaves Limited in 1972 and, over the years, has held several positions of responsibility. He was appointed Managing Director of the company in 2000 and, on his retirement in June 2011, was named Vice Chairman. He is a member of the Avantha Management Board, which formulates strategy at the Group level. He is also Chairman of the Board of Governors at Thapar University.Sudhir is a highly respected and widely recognised business leader. He was named “Outstanding Chief Executive” for 2000-2001 by the Indian Institution of Industrial Engineering. In recognition of his contribution to the Indian industry in general and the management movement in particular, the Bombay Management Association (BMA) unanimously conferred upon him the “Management Man of the Year Award” for 2005-2006. He was named Business Standard CEO of the Year for 2008-09.Sudhir has worked in various capacities with industry bodies, including BMA, Confederation of Indian Industry (CII), Indian Electrical and Electronics Manufacturers Association (IEEMA) and Nashik Industries & Manufacturers’ Association (NIMA). He was Chairman of CII’s Western Region.His interests include golf, cricket and reading.Mr. R. K. Gupta (Batch of 1965)Founder & Chairman, Laxmi Publications Group & President Emeritus BITOSA DelhiMr. Gupta is founder of Laxmi Publications Group. He has over 35 years of publishing experience. A wellknown figure in the Indian Publishing Industry, he was Ex-President, Federation of Educational Publishers in India. Apart from a distinguished personality in publishing industry, Mr. Gupta has actively taken part in promoting sports in India. He has head many international delegations. He was Secretary, Winter Games Federation of India, President, Ice Skating Association of India, Secretary, Winter Games Federation of India, Member, and Indian Olympic Association. He did Mechanical engineering from BIT Mesra.Mr. Pramod Taparia (Batch of 1966 )Founder & Chairman, Wintech TapariaMr.Pramod Taparia (popular as PT) is an entrepreneur, facilitating the food processing industry, by doing required pioneering work in India. At an age of 35 years, in 1985, PT got an award from the Vice President Shri Ramaswamy Venkataraman of India for being a "Self made Industrialist", at Delhi. Collaborating with the Swedish, in 1986, he founded a company offering international Technology & Equipments at an affordable price in India. This company, together his Scandinavian partners, pioneered Potatoes, Vegetables and Seafood processing & packaging in India. In addition to a formal degree in engineering, he went in the year 1993, for an Advance Management Program of few weeks, to a well known institute in Stockholm, Sweden.Mr. Niraj Sharan (Batch of 1976)Founder, Chairman & CEO Aura Inc.Mr. Niraj Sharan is the Founder-Chairman and CEO of Aura Inc., since 1989, a leading Global enterprise catering to the global ENERGY sector through Engineering, Manufacturing & System Integration. He is also Founder & Co-Chairman, Aurys s.r.l, Italy, a leading Technology Consulting and full service Engineering Company in Oil & Gas sector. He sits on advisory Board of several For Profit and Non-Profit companies out of USA, India & EUin Technology, Health Care and Clean Energy verticals. He is “Member, Technical Expert Committee - Government of India,under Department of Science & Technology since June 2009.”, “Special Invitee” to the US Endowment Board on US – India Joint Commission on Science and Technology formed under agreement of President Obama and Prime Minister Manmohan Singh.Mr. Sunil Jain (Batch of 1977)Chief Operating Officer & Head-Wind, Green InfraSunil is the COO of Green Infra. He has over 27 years of experience in the engineering industry, particularly in the auto and infrastructure sectors. He has extensive experience in business development, both in the domestic and international markets, and in handling commercial negotiations with customers and vendors alike. Mr. Sunil is also the President, Northern Region Council and Member National Council of Indian Wind Power Association. Sunil is a Mechanical Engineer from BIT Mesra and holds an MBA from Faculty of Management Studies, Delhi University.Mr. Rajiv Nag (Batch of 1971)Founder and Chairman, CyberQ Consulting & Senior Advisor at KPMGSenior Advisor of KPMG ,The founder and Chairman of CyberQ Consulting Pvt. Ltd., Dr. Rajiv Nag is amongst the world's top-notch consultants in the areas of Process consulting who has helped organizations put their processes in place. With over 25 years of experience around the world in the areas of Software Project Management, Quality Assurance and System Testing, Development of Software Integrated Management Systems, Functional and System Integration, Application Systems Development, System design, Strategic management consultancy, Development of Quality Management Methodology and Information Security initiatives.Shri T. Venkatesh, I.A.S. (Batch of 1979)Chief Vigilance Officer (CVO) & Board Member, NTPCShri Venkatesh is an Indian Administrative Service officer of 1988 batch of U.P. Cadre. Prior to his assignment as Jt. Secy. (DOPT) in the Ministry of Personnel & Public Grievances & Pension, he held various administrative posts including DM (Bareilly), Commissioner (Gorakhpur) and Secretary (PWD) in the state of Uttar Pradesh. He is looking after the work of CVO and also on Board of Directors of NTPC since October, 2009. He has done Mechanical engineering from BIT Mesra and is post graduate in same.Mr. Ashutosh Pande (Batch of 1983)Managing Director (India) and Global Vice President & GM ISBU at CSR Technology (India)Mr. Ashutosh specializes in market creation for new technology and products. Strategist, visionary and sharp thinker, he is currently Member Governing Council at Association of Geospatial Industries and also heads an incubation unit within the company where they are exploring avenues that will allow CSR to diversify beyond chipsets into services. He holds MS in Electrical Engineering from University of Alberta, USA and B.E. in Electronics & communication from BIT Mesra.Mr. Nirankar SaxenaDirector, Federation of Indian Chambers of Commerce and Industry (FICCI)Mr. Saxena heads the Business Information Services Network Division (BISNET) at FICCI and manages multiple project portfolios. His responsibilities include networking with leading senior Government officials,industrialists‟ and the diplomatic corps in India as well as the visiting foreign dignitaries. Prior to joining FICCI, he was Chief Executive Officer of Osprey Software Technology (P) Ltd and Director of Team Computers (P) Ltd. He holds a Page on b.e.in ComputerSciences from BIT Mesra.Mr. Ajay Pathak (Batch of 1977)Joint Secretary, Ministry of Road & Surface Transport, GOIFormer Joint Secretary at Ministry of Finance, he is now Jt. Secretary at Ministry of Road and Surface Transport. He has done his Civil Engineering from BIT Mesra.Mr. Jagdish Mitra (Batch of 1988)Chief Executive Officer of CanvasMAt CanvasM, he leads a team of over 600 associates that are focused on providing solutions that enable customers and enterprises take advantage of the mobile ecosystem. With over 20 years of experience in the areas of business development and marketing in the global information services market. Under his leadership, CanvasM has been awarded the “Best Start-Up Company” at the Mobile Content Awards 2008 held in London.Mr. Atul Kansal (Batch of 1984)Founder and Managing Director, INDUS EnviroMr. Kansal is Founder and Managing Director of INDUS Enviro and is responsible for its activities in India and the neighboring countries. He has more than 18 years of diversified consulting experience in Environmental Health & Safety (EH&S) Management particularly in EH&S Compliance and Due-Diligence Auditing. Over last 18 years, he has worked on more than 350 environmental projects in a variety of sectors. He has done his Civil engineering from BIT Mesra and Masters from IIT Roorkee.Mr. Annup Damani (Batch of 1979)Managing Director at Alloy CastMr. Damani is Managing Director at Alloy Cast (P) Ltd. Today, under his leadership, the company now boast of a capacity of over 3, 50,000 to 4, 00,000 castings per month. It has factories to cater diversified range of products and services encompassing industries like automotive, hardware, plumbing and heating controls.Mr. Abhishek Sinha (Batch of 1995)Co-founder & CEO of Eko India Financial Services Private LimitedEko democratises access to formal financial services using mobile phones as a financial identity for people at the bottom of the pyramid. Eko stands out for simplicity of user experience while still ensuring secure transactions.Eko has partnered with 1,500 retail stores bringing banking services at the next-door grocer for close to 1 million customers. Eko processes over $ 1 million every day and has processed close to half a billion dollars in transactions so far! Eko listed amongst top 10 most innovative companies in India by Fast Company | Business + Innovation!SOURCE:- www.bitmesra.ac.in

Of course not its ludicrous. They are not a threat to spreading anything.Unvaccinated Children Pose ZERO Risk to Anyone: Harvard Immunologist to LegislatorsCheck out the real threat! THE ABSOLUTE REAL ACTUAL AND BONAFIDE THREAT OF ASYMPTOMATIC CARRIERS!Vaccines can create the true greatest threat, even more insidious than vaccine shedding!Whooping cough vaccine aka pertussis vaccine DOES NOT repeat does not confer immunity!!! Let that sink in!Its masks symptoms that's it, it does not keep anyone from catching whooping cough and most importantly it does not prevent transmission of pertussis!!!That's a real threat, do you get that? Do you understand that?What that amounts to is to say those that got the pertussis vaccine can absolutely still catch whooping cough, only they dont present symptoms, yet can as asymptomatic carriers absolutely spread it and not even know they are doing so!Talk about a real threat to babies, the immunocompromised and those who are unvaccinated or can not be!Who should be banned from other countries or air travel now! People pretend vaccines are infallible manna from heaven that present no significant threats. That's garbage. Vaccines are a noble idea worth pursuing, but let's not try and pretend they are perfect and have no downsides. That's patently untrue.Not only this but people who actually get whooping cough that were unvaccinated at least give off an alarm and cough and they and those around them know to keep distance between each other. Not so with the vaccinated asymptomatic carriers. Further those unvaccinated who actually get whooping cough actually develop life long immunity unlike the vaccinated.Onced vaccinated you will never be able to develop life long immunity. You will always be susceptible to catching whooping cough and as an asymptomatic carrier be a vector for spreading the virus. I consider this permanent damage to the immune system!It's far more wise to simply load up on vitamin D when infected and develop life long immunity vs accept the lemon option of inferior effects of the pertussis vaccine.The vaccinated are a far more significant threat due to asymptomatic carriers. Not even considering shedding of live attenuated viruses from this category of vaccines.If you read the first link you will see this is true of other vaccines too. Asymptomatic carriers are a major and profound threat to society, especially babies, the immunocompromised and the unvaccinated. Far far more so than the unvaccinated, who are a tiny fraction of the population who really at most pose a threat to each other, especially if vaccines have the efficacy they claim. The vaccinated should not fear the unvaccinated if vaccines are all they are cracked up to be.Measles is another example where there is a problem of asymptomatic carriers and more. According to a study conducted by the WHO, but kept under wraps measles vaccine wanes after 2 to 4 years. You dont get life long immunity like those who really get measles. In fact you become 14 times more likely to contract measles as compared to the unvaccinated. You become an asymptomatic carrier and can infect, babies, the immunocompromised and those who are unvaccinated or can't be vaccinated.Talk about a real and present danger! Should pro vaccine people be banned from public places? Not permitted to travel, because they are proven threats, especially as compared to the unvaccinated?Don't like to read about evidence? Then watch the video.Pro-Vaccine vs Anti-Vaccine? WHERE'S THE SCIENCE? WHERE'S THE PLAGUE? - HERD IMMUNITYNow if you need to see further peer reviewed evidence and the links to the papers check out this great information from Bella May!Vaccine efficacy WANES!!! Think hour glass.Many vaccine products do lose effectiveness over time. This attribute of vaccine products to wane, negatively impacts disease prevention at a population level. For instance, wild measles virus infection provides lifelong immunity against measles disease. [1,2,3,4,5] The CDC states that Measles vaccine provides lifelong protection in ~93% of individuals after one dose, and an additional 2–4% gain this protection after two doses of measles vaccine, [6] in this way the measles vaccine is reportedly 97% effective in providing lifelong protection in fully vaccinated cohorts.However, recent data shows that measles vaccine wanes within ~ 7.5 years on average following the second dose in approximately 10% of children and their peers soon follow. Measles vaccine does not provide lifelong protection against measles virus like wild measles infection does. [7,8] Because the US schedule primarily only vaccinates young children against measles virus, a significant portion of vaccinated female children will no longer have protective antibodies against measles by adulthood, when these women become mothers they can not transfer the protective antibodies against measles virus needed to protect their infants, leaving many of today’s very young infants vulnerable to measles disease. [9]We are told by health authorities that measles disease prevention requires 95% of the population to have sufficient antibodies against measles virus, a 10% + vaccine failure rate in adults demonstrates that protection at the population level can not be achieved under the current US recommendations and with the current measles vaccine products even if 100% of the population received measles vaccine. Modern measles outbreaks are now often comprised of a significant number of adolescents, infants,and adults. [10,11,12,13,14,15] Additional measles vaccine doses appear to have little boosting effect in fully vaccinated persons…[16,17,18]According to the science, this dynamic of measles vaccine to wane [19,20,21,22,23] has resulted in fewer measles immunoglobulin donors that ‘those who cannot be vaccinated’ rely upon for protection during measles outbreaks. Although, giving additional measles vaccine doses to these donors with waned vaccine derived measles antibodies does result in a doubling of measles antibody titers, the titers are still insufficient to meet FDA requirements for immunoglobulin products and the titers return to baseline within a few months. [24,25] This indicates that measles vaccine has diminishing returns with subsequent doses. We find ourselves in the uncomfortable circumstance that mass vaccination with the current vaccine has left many infants, adolescents, adults and immunocompromised persons vulnerable to measles disease - perhaps indefinitely.Outbreaks of measles occur amongst individuals with partially waned measles titers, these individuals run a course of atypical measles disease and are contagious. The CDC reported an outbreak in an adult population where the primary patient had documentation of receipt of 3 doses of measles-containing vaccine, displayed modified measles disease symptoms and subsequently transmitted wild measles to 9 vaccinated contacts whom the majority had received 2 doses of measles vaccine. - “Measles Outbreak in a Highly Vaccinated Population” https://www.cdc.gov/mmwr/volumes...This defect in the measles vaccine product to allow replication of measles virus inside vaccinated hosts with partial protection may promote viral mutations that result in selection of vaccine resistant measles strains of increased virulence. [26] Mutated strains of measles virus with novel disease symptoms of increased virulence have been found circulating in India. [27,28] In addition, mutated measles virus that is vaccine resistant has also been circulating in African countries [29,30], France and Great Britain [30].Many vaccines do not contribute to herd immunity, such as acellular Pertussis, [31,32] Inactivated Polio, [33,34] and rotavirus. [35,36,37] Recipients of these vaccines may garner temporary individual protection against disease symptoms, but are able to become infected, colonize and transmit wild disease to others regardless of vaccination status or antibody titers. In order for herd immunity to be achievable through vaccination, it is a requirement of these products to prevent colonization, infection, and transmission to others….if this is not achieved then herd immunity can not exist through vaccination.Reference;[1] “These studies confirm the observation that one attack of measles is followed by lifelong immunity.”—“Studies on immunity to measles” https://www.jpeds.com/article/S0...[2] “The relevant components are durable for a lifetime”. - “Measles active and passive immunity in a worldwide perspective.[3] “most patients develop lifelong immunity after recovery or vaccination from this infection” - Persistent measles virus infection enhances major histocompatibility complex class I expression and immunogenicity of murine neuroblastoma cells[4] ”hosts that survive the infection normally develop lifelong immunity.” - Morbillivirus Infections: An Introduction[5] “Similar to immunity after natural measles infection, live measles vaccine-induced immunity has been thought to be lifelong.“ - Duration of live measles vaccine-induced immunity.[6] “The second dose of measles-containing vaccine primarily was intended to induce immunity in the small percentage of persons who did not seroconvert after vaccination with the first dose of vaccine (primary vaccine failure).” - CDC 2013 https://www.cdc.gov/mmwr/pdf/rr/...[7] “even with two documented doses of measles vaccine, our laboratory demonstrated that 8.9% of 763 healthy children immunized a mean of 7.4 years earlier lacked protective levels of circulating measles-specific neutralizing antibodies, suggesting that even two doses of the current vaccine may be insufficient at the population level." - “The re-emergence of measles in developed countries: Time to develop the next-generation measles vaccines?” http://www.edwardjennersociety.o...[8] “A serologic study has shown that up to 15% of persons lose detectable measles specific antibody, measured with standard techniques, within the 16 years following vaccination.” - “Measles Outbreak among Vaccinated High School Students -- Illinois” https://www.cdc.gov/mmwr//previe...[9] “In recent years, the new vaccination regime, too, has been failing, with widespread outbreaks again occurring, including among those who have received the recommended dose and especially among infants too young to be vaccinated, and thus unprotected because their mothers had been vaccinated. Now health experts, scrambling to find solutions, are suggesting numerous reforms, including earlier child vaccinations and second doses for adults. Clearly, the science is not settled.” (Financial Post, 2014) http://business.financialpost.co...[10]“with increase in overall coverage of vaccination, there is a rise in incidence of measles in vaccinated individuals. The age profile also shifts to higher age groups.” - “Measles outbreak in adults: A changing epidemiological pattern.” http://www.mjdrdypu.org/article....[11] “The epidemiology of measles in Cape Town has thus changed as evinced in this epidemic, with an increase in the number of cases occurring in older, previously vaccinated children. The possible reasons for this include both primary and secondary vaccine failure.” - “The 1992 measles epidemic in Cape Town--a changing epidemiological pattern.” https://www.ncbi.nlm.nih.gov/pub...[12] “Measles outbreaks can occur among highly vaccinated college populations." - “A measles outbreak at a college with a prematriculation immunization requirement.” https://www.ncbi.nlm.nih.gov/pub...[13] In a measles outbreak from March 1991 to April 1992 in Rio de Janeiro, “76.4% of those suspected to be infected had received measles vaccine before their first birthday. The results of this work show changes in age distribution of measles leading to sizeable outbreaks among teenagers and young adults.” - “Clinical and epidemiological findings during a measles outbreak occurring in a population with a high vaccination coverage.” https://www.ncbi.nlm.nih.gov/pub...[14] “Notified cases were mainly seen in pre-vaccination age children and adults aged from 20 to 39 years.” - “Assessing the transmission dynamics of measles in Japan, 2016”. https://www.sciencedirect.com/sc...[15] “The results of this work show changes in age distribution of measles leading to sizeable outbreaks among teenagers and young adults.” - “Clinical and epidemiological findings during a measles outbreak occurring in a population with a high vaccination coverage.” https://www.ncbi.nlm.nih.gov/pub...[16] “Approximately 1½ years after the initial vaccination, 46% of the uninfected children maintained very low levels of neutralizing antibody, but did not have a measurable haemagglutination-inhibition titre. Revaccination did not elicit an IgM response in most children, but stimulated anti-measles IgG production in all of them. In 36% of the children, the IgG titres fell again within three months to levels that may permit reinfection.” - “Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination”. Home - PMC - NCBI...[17] “Most subjects were seropositive before MMR3 receipt, and very few had a secondary immune response after MMR3 receipt. Similarly, CMI and avidity analyses showed minimal qualitative improvements in immune response after MMR3 receipt. We did not find compelling data to support a routine third dose of MMR vaccine.” - “Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.” https://academic.oup.com/jid/art...[18] “Early measles vaccination provides immediate protection in the majority of infants, but long-term neutralizing antibody responses are reduced compared to infants vaccinated at a later age. Additional vaccination at 14 months of age does not improve this. Long-term, this may result in an increasing number of children susceptible to measles.” - Early measles vaccination during an outbreak in The Netherlands: reduced short and long-term antibody responses in children vaccinated before 12 months of age. https://www.ncbi.nlm.nih.gov/pub...[19] “Progressive decline in antibody levels and seropositivity were observed over time after vaccination in infants, adolescents, and young adults. Waning levels of measles antibodies with increasing time post-vaccination suggests that measles susceptibility is potentially increasing in Korea. This trend may be related to limitations of vaccine-induced immunity in the absence of natural boosting by the wild virus, compared to naturally acquired immunity triggered by measles infection.” - “An increasing, potentially measles-susceptible population over time after vaccination in Korea”. https://www.sciencedirect.com/sc...[20] “There was a significant declining trend of seropositivity with age in vaccinees. The overall seroprevalence of measles was not sufficient for herd immunity. Waning vaccine-induced immunity weakened the population immunity to measles.” - “Waning population immunity to measles in Taiwan”. https://www.sciencedirect.com/sc...[21] Waning vaccine effectiveness shifts susceptibility to an age where severity of complications is greater. “Our calculations show that negative outcomes are 4·5 times worse for measles, 2·2 times worse for chickenpox, and 5·8 times worse for rubella than would be expected in a pre-vaccine era in which the average age at infection would have been lower. As vaccination makes preventable illness rarer, for some diseases, it also increases the expected severity of each case.” - “Dangers of vaccine refusal near the herd immunity threshold: A modeling study”.https://www.researchgate.net/pub...[22] “Our results show that MMR vaccine-induced antibodies wane significantly after the second dose. According to epidemiological data, the protection induced by MMR vaccination in Finland seems to persist at least until early adulthood.” - “Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: A 20-year follow-up.” https://www.scopus.com/record/di...[23] “Results show that the cohort model is identifiable and qualitatively captures the decline in seropositivity observed in older children.” - “Estimating vaccine coverage from serial trivariate serologic data in the presence of waning immunity.” - https://www.scopus.com/record/di...[24] “measles virus-neutralizing antibodies in intravenous immunoglobulins” - 2006. https://academic.oup.com/jid/art...[25] “Measles virus neutralizing antibodies in intravenous immunoglobulins: is increase in revaccination in plasma donors possible?”-2017. Oregon Legislative Information System...[26] “Since there are still fitness benefits of virulence, more aggressive strains will spread in vaccinated populations because they are now less likely to kill the host. Even if vaccination reduces pathogen titers and transmission rates, virulent strains will still produce more transmission stages than less virulent strains. In fact, in an immunized host, they may produce disproportionately more transmission stages if immunity is more effective against less aggressive strains. Consequently, vaccinated individuals create the conditions that favor the spread of intrinsically more virulent parasites” - “Pathogen evolution in a vaccinated world.” http://thereadgroup.net/wp-conte...[27] Scientists investigating an outbreak of encephalitis among adults in the town of Siliguri, in West Bengal, told the health ministry this week that the disease was caused by a mutant measles virus that affects the brain, lungs, or kidneys. This is India's third outbreak since 1998 of a highly fatal illness involving the brain or the kidneys and attributed to the measles virus.” - “Indian scientists warn of mutant measles virus” Home - PMC - NCBI...[28] “The patients from whom the samples were collected had been suffering from acute renal failure, neurological disorders and encephalopathy, These are new symptoms for measles, the new measles strain has not been causing the typical rash.” - “Mutant measles strains hit nation” https://timesofindia.indiatimes....[29] “Mutant variants of the [measles] virus are now circulating in Africa. They are resistant to half of the antibodies that humans produce when vaccinated.” - “Super-measles warning”. http://news.bbc.co.uk/2/hi/healt...[30] “gene sequences of these 2 groups confirmed that they represent clearly definable, sequence-divergent D4 subgenotypes, which we named subgenotypes D4.1 and D4.2. The subgenotype D4.1 MeVs were isolated predominantly in Kenya and Ethiopia, whereas the MAb-resistant subgenotype D4.2 MeVs were isolated predominantly in France and Great Britain, countries with higher vaccine coverage rates. Interestingly, D4.2 subgenotype viruses showed a trend toward diminished susceptibility to neutralization by human sera pooled from approximately 60 to 80 North American donors. Escape from MAb neutralization may be a powerful epidemiological surveillance tool to monitor the evolution of new MeV subgenotypes.” - “Antigenic Drift Defines a New D4 Subgenotype of Measles Virus”. https://www.researchgate.net/pub...[31] The BU School of Public Health estimates that 50% of the population is colonized with pertussis. “Resurgence of Whooping Cough May Owe to Vaccine’s Inability to Prevent Infections”. https://www.bu.edu/sph/2017/09/2...[32] According to an FDA press release and cited study, acellular pertussis (DTaP) vaccine does not prevent infection or spread of pertussis; “Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model”. Home - PMC - NCBI...https://web.archive.org/web/20131130004447/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376937.[33] “IPV, an inactivated polio vaccine, which induces only very low levels of immunity to poliovirus inside the gut, and as a result provides individual protection against polio, but unlike OPV, IPV cannot prevent the spread of wild poliovirus.” - World Health Organization http://www.who.int/immunization_...[34] “91% of children receiving no IPV (control group B) were colonized with live attenuated poliovirus upon deliberate experimental inoculation. Children who were vaccinated with IPV (groups A and C) were similarly colonized at the rate of 94-97%. High counts of live virus were recovered from the stool of children in all groups. These results make it clear that IPV cannot be relied upon for the control of polioviruses.” - “Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba.” http://www.ncbi.nlm.nih.gov/pubm...[35] “We document here the occurrence of vaccine-derived rotavirus (RotaTeq [Merck and Co, Whitehouse Station, NJ]) transmission from a vaccinated infant to an older, unvaccinated sibling, resulting in symptomatic rotavirus gastroenteritis that required emergency department care. Results of our investigation suggest that reassortment between vaccine component strains of genotypes P7[5]G1 and P1A[8]G6 occurred during replication either in the vaccinated infant or in the older sibling, raising the possibility that this reassortment may have increased the virulence of the vaccine-derived virus.” https://www.ncbi.nlm.nih.gov/pub...[36] “In fact, transmission of these two rotavirus vaccines or vaccine-reassortment strains to unvaccinated contacts has been detected, even in the absence of symptoms.” https://www.ncbi.nlm.nih.gov/pub...[37] “15 transmission cases were reported in 80 evaluable twins who received placebo and the transmission rate was 18.8%” - “Horizontal transmission of a human rotavirus vaccine strain--a randomized, placebo-controlled study in twins.” Horizontal transmission of a human rotavirus vaccine strain--a randomized, placebo-controlled study in twins.

They are not causing damage they are attempting to correct it.Vaccines don't just have upsides they have real problems too. Although vaccines can save lives, is that all that matters?Everyone assesses risks differently, we are all unique and a one size fits all approach is unsound. So is not comparing vaccinated to unvaccinated children or doing randomized double blind inert placebo controlled SAFETY testing.We can't do this for efficacy because its unethical to expose people to a disease or a virus. But we can do and should be doing randomized double blind inert placebo controlled safety studies on every individual vaccine, on each and every component, on vaccines in combination, as well as on the entire CDC schedule. Safety trumps efficacy every time.Pro vaccine advocates tend to only lament on the potential for efficacy of vaccines, like skydivers that only speak of the thrill of the jump, as if danger is non existent.Vaccine safety proponents focus on the downsides of vaccines and do not pretend they are not real.They both assess the risks differently.People think vaccines have no dangers because that's what the mainstream narrative is. They are owned by big pharma, big pharma pays for like 70% of ad revenues, big pharma executives are on the board of directors for all but CBS. Big pharma lies, cheats, bribes, creates fake medical journals, creates hit lists of doctors and people to destroy and have killed more people than the Vietnam war. Just look at vioxx, 30,000 at minimum upwards of 500,000 people by the higher estimates.It took that much death for them to admit guilt and this is for a product they are liable for. Vaccines manufacturers can not be sued, the American people are left to pay for their failures. In effect vaccine manufacturers have the only business model where you can profit from failure.How people can discount this and presume for a product line they have zero liability for they are going to be honest, forthright and full of integrity is a very special form of cognitive dissonance that is astonishing.The PRECAUTIONARY principle is a real legal principle that should always be paramount in the face of uncertainty. Big pharma defiles this principle and would have people believe the benefits outweigh the risks in all possible cases.That's not true for all people, and a one size fits all approach is folly.Should we give up on vaccines? No. We should work to make them safe as well as efficacious. But safety is more important I would argue, more important by a long shot. The science is not settled not by a long shot, the very concept of settled science isn't even scientific its dogmatic.Peer reviewed evidence is important to all sides. If you are not familiar with the evidence on both sides of this issue you can't really know what you're talking about.There is evidence both for and against and if all you know about is one side or the other you are biased.I am partly biased because I have 4 sons, and I believed whole heartedly vaccines posed no threats and were only possibly good. I vaccinated my sons and the first 3 all developed autism directly after vaccination.I was suspicious and vaccinated at different ages and the results were the same. The first 3 developed autism all at different ages, but directly after vaccination.The 3rd suffered anaphylactic shock, 3 hours after vaccination. His skin got blotchy before we even got home from the doctors office, we went directly back and were given a cream. When we got home he started to turn blue, we called the ambulance and he was rushed to the Emergency Room.His brain had swelling and cut off oxygen and he suffered encephalopathy. He lost all speech, counting abilities, toilet training and much more. He is now 12. Our 4th son is the only 1 with no autism yet. He only had vitamin k and the first round of Dtap. He is the only one without an IEP. His intelligence is well beyond his brothers, eye contact, coordination and speech are stellar.Vaccines have a number of problems and people need to be aware of them as much if not more then the potential benefits. We can't pretend risks don't exist or try to downplay them.Look at the only peer reviewed evidence comparing the vaccinated to the unvaccinated In the United States.MawsonStudyHealthOutcomes5.8.2017.pdfMawsonStudyPretermBirth5.8.2017.pdfThese studies are published in a scientific journal and have never been retracted.The author is conducting a larger study comparing the vaccinated to the unvaccinated via the Medicaid database.Outside the US, the DTP vaccine recipients have been shown to have a 5 to 10 times higher mortality rates. They get coverage for diphtheria, tetanus and pertussis but wind up dying from other causes at a much higher rate than the unvaccinated.That is called unintended consequences, and is also a downside to vaccines. So should we end the vaccine program? No. But we should certainly want to address its failures and be real about it.People think antivaxx people put people at risk, and even if that's true vaccines also put people at risk.Unvaccinated Children Pose ZERO Risk to Anyone: Harvard Immunologist to LegislatorsIt can be said the vaccinated pose significant risks too and far greater ones too. Take vaccine shedding, more cases of polio from vaccine derived polio strains. Measles MMR vaccine also sheds. 39% of the Disney outbreak were from the vaccine derived strain.Then there is asymptomatic carriers, this is the biggest threat of all! A bigger threat then the unvaccinated by far. Asymptomatic carriers threaten the unvaccinated, the vaccinated, babies and immunocompromised.Take pertussis vaccine, it does not prevent transmission. It merely masks symptoms. Meaning you can totally have whooping cough and not even know it, if you have been vaccinated. You can fully infect innocent people without even being aware.Look at the California outbreak. All the kids that got it were vaccinated and none of the unvaccinated kids did. Unvaccinated children that get whooping cough show symptoms and its obvious to stay away, not so with asymptomatic carriers. This is a far greater threat. It's a real downside to vaccines. Should this be ignored and swept under the rug? Or addressed and admitted to?People with actual whooping cough get life long immunity, not so of those who get vaccinated. Same with measles.2 to 4 years after MMR your immunity can wane. You can catch and infect others and show no symptoms. Not only that but you are also 14 times more likely to contract measles then the unvaccinated. The rate of contraction is far greater, and the number of vaccinated are far greater, thus the rate at which the vaccinated can infect others is substantially greater than the potential from the unvaccinated. So who is the greater threat? See the WHO study showing this here: Pro-Vaccine vs Anti-Vaccine? WHERE'S THE SCIENCE? WHERE'S THE PLAGUE? - HERD IMMUNITYThose with real measles get life long immunity not some limited immunity.Consider the peer reviewed evidence put forward by Bella May. The peer reviewed evidence paints the unseen picture. Vaccines dont just have an upside. We must therefore recognize these risks and address them, not mandate something uncertain for all.By Bella May:Many vaccine products do lose effectiveness over time. This attribute of vaccine products to wane, negatively impacts disease prevention at a population level. For instance, wild measles virus infection provides lifelong immunity against measles disease. [1,2,3,4,5] The CDC states that Measles vaccine provides lifelong protection in ~93% of individuals after one dose, and an additional 2–4% gain this protection after two doses of measles vaccine, [6] in this way the measles vaccine is reportedly 97% effective in providing lifelong protection in fully vaccinated cohorts.However, recent data shows that measles vaccine wanes within ~ 7.5 years on average following the second dose in approximately 10% of children and their peers soon follow. Measles vaccine does not provide lifelong protection against measles virus like wild measles infection does. [7,8] Because the US schedule primarily only vaccinates young children against measles virus, a significant portion of vaccinated female children will no longer have protective antibodies against measles by adulthood, when these women become mothers they can not transfer the protective antibodies against measles virus needed to protect their infants, leaving many of today’s very young infants vulnerable to measles disease. [9]We are told by health authorities that measles disease prevention requires 95% of the population to have sufficient antibodies against measles virus, a 10% + vaccine failure rate in adults demonstrates that protection at the population level can not be achieved under the current US recommendations and with the current measles vaccine products even if 100% of the population received measles vaccine. Modern measles outbreaks are now often comprised of a significant number of adolescents, infants,and adults. [10,11,12,13,14,15] Additional measles vaccine doses appear to have little boosting effect in fully vaccinated persons…[16,17,18]According to the science, this dynamic of measles vaccine to wane [19,20,21,22,23] has resulted in fewer measles immunoglobulin donors that ‘those who cannot be vaccinated’ rely upon for protection during measles outbreaks. Although, giving additional measles vaccine doses to these donors with waned vaccine derived measles antibodies does result in a doubling of measles antibody titers, the titers are still insufficient to meet FDA requirements for immunoglobulin products and the titers return to baseline within a few months. [24,25] This indicates that measles vaccine has diminishing returns with subsequent doses. We find ourselves in the uncomfortable circumstance that mass vaccination with the current vaccine has left many infants, adolescents, adults and immunocompromised persons vulnerable to measles disease - perhaps indefinitely.Outbreaks of measles occur amongst individuals with partially waned measles titers, these individuals run a course of atypical measles disease and are contagious. The CDC reported an outbreak in an adult population where the primary patient had documentation of receipt of 3 doses of measles-containing vaccine, displayed modified measles disease symptoms and subsequently transmitted wild measles to 9 vaccinated contacts whom the majority had received 2 doses of measles vaccine. - “Measles Outbreak in a Highly Vaccinated Population” https://www.cdc.gov/mmwr/volumes...This defect in the measles vaccine product to allow replication of measles virus inside vaccinated hosts with partial protection may promote viral mutations that result in selection of vaccine resistant measles strains of increased virulence. [26] Mutated strains of measles virus with novel disease symptoms of increased virulence have been found circulating in India. [27,28] In addition, mutated measles virus that is vaccine resistant has also been circulating in African countries [29,30], France and Great Britain [30].Many vaccines do not contribute to herd immunity, such as acellular Pertussis, [31,32] Inactivated Polio, [33,34] and rotavirus. [35,36,37] Recipients of these vaccines may garner temporary individual protection against disease symptoms, but are able to become infected, colonize and transmit wild disease to others regardless of vaccination status or antibody titers. In order for herd immunity to be achievable through vaccination, it is a requirement of these products to prevent colonization, infection, and transmission to others….if this is not achieved then herd immunity can not exist through vaccination.Reference;[1] “These studies confirm the observation that one attack of measles is followed by lifelong immunity.”—“Studies on immunity to measles” https://www.jpeds.com/article/S0...[2] “The relevant components are durable for a lifetime”. - “Measles active and passive immunity in a worldwide perspective.[3] “most patients develop lifelong immunity after recovery or vaccination from this infection” - Persistent measles virus infection enhances major histocompatibility complex class I expression and immunogenicity of murine neuroblastoma cells[4] ”hosts that survive the infection normally develop lifelong immunity.” - Morbillivirus Infections: An Introduction[5] “Similar to immunity after natural measles infection, live measles vaccine-induced immunity has been thought to be lifelong.“ - Duration of live measles vaccine-induced immunity.[6] “The second dose of measles-containing vaccine primarily was intended to induce immunity in the small percentage of persons who did not seroconvert after vaccination with the first dose of vaccine (primary vaccine failure).” - CDC 2013 https://www.cdc.gov/mmwr/pdf/rr/...[7] “even with two documented doses of measles vaccine, our laboratory demonstrated that 8.9% of 763 healthy children immunized a mean of 7.4 years earlier lacked protective levels of circulating measles-specific neutralizing antibodies, suggesting that even two doses of the current vaccine may be insufficient at the population level." - “The re-emergence of measles in developed countries: Time to develop the next-generation measles vaccines?” http://www.edwardjennersociety.o...[8] “A serologic study has shown that up to 15% of persons lose detectable measles specific antibody, measured with standard techniques, within the 16 years following vaccination.” - “Measles Outbreak among Vaccinated High School Students -- Illinois” https://www.cdc.gov/mmwr//previe...[9] “In recent years, the new vaccination regime, too, has been failing, with widespread outbreaks again occurring, including among those who have received the recommended dose and especially among infants too young to be vaccinated, and thus unprotected because their mothers had been vaccinated. Now health experts, scrambling to find solutions, are suggesting numerous reforms, including earlier child vaccinations and second doses for adults. Clearly, the science is not settled.” (Financial Post, 2014) http://business.financialpost.co...[10]“with increase in overall coverage of vaccination, there is a rise in incidence of measles in vaccinated individuals. The age profile also shifts to higher age groups.” - “Measles outbreak in adults: A changing epidemiological pattern.” http://www.mjdrdypu.org/article....[11] “The epidemiology of measles in Cape Town has thus changed as evinced in this epidemic, with an increase in the number of cases occurring in older, previously vaccinated children. The possible reasons for this include both primary and secondary vaccine failure.” - “The 1992 measles epidemic in Cape Town--a changing epidemiological pattern.” https://www.ncbi.nlm.nih.gov/pub...[12] “Measles outbreaks can occur among highly vaccinated college populations." - “A measles outbreak at a college with a prematriculation immunization requirement.” https://www.ncbi.nlm.nih.gov/pub...[13] In a measles outbreak from March 1991 to April 1992 in Rio de Janeiro, “76.4% of those suspected to be infected had received measles vaccine before their first birthday. The results of this work show changes in age distribution of measles leading to sizeable outbreaks among teenagers and young adults.” - “Clinical and epidemiological findings during a measles outbreak occurring in a population with a high vaccination coverage.” https://www.ncbi.nlm.nih.gov/pub...[14] “Notified cases were mainly seen in pre-vaccination age children and adults aged from 20 to 39 years.” - “Assessing the transmission dynamics of measles in Japan, 2016”. https://www.sciencedirect.com/sc...[15] “The results of this work show changes in age distribution of measles leading to sizeable outbreaks among teenagers and young adults.” - “Clinical and epidemiological findings during a measles outbreak occurring in a population with a high vaccination coverage.” https://www.ncbi.nlm.nih.gov/pub...[16] “Approximately 1½ years after the initial vaccination, 46% of the uninfected children maintained very low levels of neutralizing antibody, but did not have a measurable haemagglutination-inhibition titre. Revaccination did not elicit an IgM response in most children, but stimulated anti-measles IgG production in all of them. In 36% of the children, the IgG titres fell again within three months to levels that may permit reinfection.” - “Inadequate immunity to measles in children vaccinated at an early age: effect of revaccination”. Home - PMC - NCBI...[17] “Most subjects were seropositive before MMR3 receipt, and very few had a secondary immune response after MMR3 receipt. Similarly, CMI and avidity analyses showed minimal qualitative improvements in immune response after MMR3 receipt. We did not find compelling data to support a routine third dose of MMR vaccine.” - “Measles Virus Neutralizing Antibody Response, Cell-Mediated Immunity, and Immunoglobulin G Antibody Avidity Before and After Receipt of a Third Dose of Measles, Mumps, and Rubella Vaccine in Young Adults.” https://academic.oup.com/jid/art...[18] “Early measles vaccination provides immediate protection in the majority of infants, but long-term neutralizing antibody responses are reduced compared to infants vaccinated at a later age. Additional vaccination at 14 months of age does not improve this. Long-term, this may result in an increasing number of children susceptible to measles.” - Early measles vaccination during an outbreak in The Netherlands: reduced short and long-term antibody responses in children vaccinated before 12 months of age. https://www.ncbi.nlm.nih.gov/pub...[19] “Progressive decline in antibody levels and seropositivity were observed over time after vaccination in infants, adolescents, and young adults. Waning levels of measles antibodies with increasing time post-vaccination suggests that measles susceptibility is potentially increasing in Korea. This trend may be related to limitations of vaccine-induced immunity in the absence of natural boosting by the wild virus, compared to naturally acquired immunity triggered by measles infection.” - “An increasing, potentially measles-susceptible population over time after vaccination in Korea”. https://www.sciencedirect.com/sc...[20] “There was a significant declining trend of seropositivity with age in vaccinees. The overall seroprevalence of measles was not sufficient for herd immunity. Waning vaccine-induced immunity weakened the population immunity to measles.” - “Waning population immunity to measles in Taiwan”. https://www.sciencedirect.com/sc...[21] Waning vaccine effectiveness shifts susceptibility to an age where severity of complications is greater. “Our calculations show that negative outcomes are 4·5 times worse for measles, 2·2 times worse for chickenpox, and 5·8 times worse for rubella than would be expected in a pre-vaccine era in which the average age at infection would have been lower. As vaccination makes preventable illness rarer, for some diseases, it also increases the expected severity of each case.” - “Dangers of vaccine refusal near the herd immunity threshold: A modeling study”.https://www.researchgate.net/pub...[22] “Our results show that MMR vaccine-induced antibodies wane significantly after the second dose. According to epidemiological data, the protection induced by MMR vaccination in Finland seems to persist at least until early adulthood.” - “Persistence of measles, mumps, and rubella antibodies in an MMR-vaccinated cohort: A 20-year follow-up.” https://www.scopus.com/record/di...[23] “Results show that the cohort model is identifiable and qualitatively captures the decline in seropositivity observed in older children.” - “Estimating vaccine coverage from serial trivariate serologic data in the presence of waning immunity.” - https://www.scopus.com/record/di...[24] “measles virus-neutralizing antibodies in intravenous immunoglobulins” - 2006. https://academic.oup.com/jid/art...[25] “Measles virus neutralizing antibodies in intravenous immunoglobulins: is increase in revaccination in plasma donors possible?”-2017. Oregon Legislative Information System...[26] “Since there are still fitness benefits of virulence, more aggressive strains will spread in vaccinated populations because they are now less likely to kill the host. Even if vaccination reduces pathogen titers and transmission rates, virulent strains will still produce more transmission stages than less virulent strains. In fact, in an immunized host, they may produce disproportionately more transmission stages if immunity is more effective against less aggressive strains. Consequently, vaccinated individuals create the conditions that favor the spread of intrinsically more virulent parasites” - “Pathogen evolution in a vaccinated world.” http://thereadgroup.net/wp-conte...[27] Scientists investigating an outbreak of encephalitis among adults in the town of Siliguri, in West Bengal, told the health ministry this week that the disease was caused by a mutant measles virus that affects the brain, lungs, or kidneys. This is India's third outbreak since 1998 of a highly fatal illness involving the brain or the kidneys and attributed to the measles virus.” - “Indian scientists warn of mutant measles virus” Home - PMC - NCBI...[28] “The patients from whom the samples were collected had been suffering from acute renal failure, neurological disorders and encephalopathy, These are new symptoms for measles, the new measles strain has not been causing the typical rash.” - “Mutant measles strains hit nation” https://timesofindia.indiatimes....[29] “Mutant variants of the [measles] virus are now circulating in Africa. They are resistant to half of the antibodies that humans produce when vaccinated.” - “Super-measles warning”. http://news.bbc.co.uk/2/hi/healt...[30] “gene sequences of these 2 groups confirmed that they represent clearly definable, sequence-divergent D4 subgenotypes, which we named subgenotypes D4.1 and D4.2. The subgenotype D4.1 MeVs were isolated predominantly in Kenya and Ethiopia, whereas the MAb-resistant subgenotype D4.2 MeVs were isolated predominantly in France and Great Britain, countries with higher vaccine coverage rates. Interestingly, D4.2 subgenotype viruses showed a trend toward diminished susceptibility to neutralization by human sera pooled from approximately 60 to 80 North American donors. Escape from MAb neutralization may be a powerful epidemiological surveillance tool to monitor the evolution of new MeV subgenotypes.” - “Antigenic Drift Defines a New D4 Subgenotype of Measles Virus”. https://www.researchgate.net/pub...[31] The BU School of Public Health estimates that 50% of the population is colonized with pertussis. “Resurgence of Whooping Cough May Owe to Vaccine’s Inability to Prevent Infections”. https://www.bu.edu/sph/2017/09/2...[32] According to an FDA press release and cited study, acellular pertussis (DTaP) vaccine does not prevent infection or spread of pertussis; “Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model”. Home - PMC - NCBI...https://web.archive.org/web/20131130004447/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376937.[33] “IPV, an inactivated polio vaccine, which induces only very low levels of immunity to poliovirus inside the gut, and as a result provides individual protection against polio, but unlike OPV, IPV cannot prevent the spread of wild poliovirus.” - World Health Organization http://www.who.int/immunization_...[34] “91% of children receiving no IPV (control group B) were colonized with live attenuated poliovirus upon deliberate experimental inoculation. Children who were vaccinated with IPV (groups A and C) were similarly colonized at the rate of 94-97%. High counts of live virus were recovered from the stool of children in all groups. These results make it clear that IPV cannot be relied upon for the control of polioviruses.” - “Randomized, placebo-controlled trial of inactivated poliovirus vaccine in Cuba.” http://www.ncbi.nlm.nih.gov/pubm...[35] “We document here the occurrence of vaccine-derived rotavirus (RotaTeq [Merck and Co, Whitehouse Station, NJ]) transmission from a vaccinated infant to an older, unvaccinated sibling, resulting in symptomatic rotavirus gastroenteritis that required emergency department care. Results of our investigation suggest that reassortment between vaccine component strains of genotypes P7[5]G1 and P1A[8]G6 occurred during replication either in the vaccinated infant or in the older sibling, raising the possibility that this reassortment may have increased the virulence of the vaccine-derived virus.” https://www.ncbi.nlm.nih.gov/pub...[36] “In fact, transmission of these two rotavirus vaccines or vaccine-reassortment strains to unvaccinated contacts has been detected, even in the absence of symptoms.” https://www.ncbi.nlm.nih.gov/pub...[37] “15 transmission cases were reported in 80 evaluable twins who received placebo and the transmission rate was 18.8%” - “Horizontal transmission of a human rotavirus vaccine strain--a randomized, placebo-controlled study in twins.” Horizontal transmission of a human rotavirus vaccine strain--a randomized, placebo-controlled study in twins.